Mimedx (MDXG) Notes Payables (2010 - 2011)
Mimedx recorded quarterly Notes Payables of $1.3 million in Q4 2011, up 24.44% quarter-over-quarter from $1.0 million in Q3 2011, and up 221.24% year-over-year from $403432.0 in Q4 2010.
Mimedx's Notes Payables history runs 2 years deep, the most recent figure standing at $1.3 million for Q4 2011.
- In Q4 2011, Notes Payables rose 221.24% year-over-year to $1.3 million; the TTM figure through Dec 2011 stood at $1.3 million (up 221.24% YoY), while the FY2011 annual figure was $1.3 million, up 221.24% from the prior year.
- Notes Payables came in at $1.3 million for Q4 2011 at Mimedx, up from $1.0 million in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $1.3 million in Q4 2011 to a low of $45540.0 in Q2 2011.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | 1.30 Mn |
| Sep 30, 2011 | 1.04 Mn |
| Jun 30, 2011 | 45,540.00 |
| Dec 31, 2010 | 403,432.00 |